EOLS Q4 2022 Earnings — Evolus, Inc. Revenue & Financial Results | Market Cap Arena

EOLSEvolus, Inc.

$353M

Q4 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$44M+25.9% YoY

Gross Profit

$30M69.4% margin

Operating Income

-$11M-24.4% margin

Net Income

-$13M-30.2% margin

EPS (Diluted)

$-0.23

QoQ Revenue Growth

+28.8%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$10M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$178M

Total Liabilities

$159M

Stockholders' Equity

$18M

Cash & Equivalents

$54M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$44M	$35M	+25.9%
Gross Profit	$30M	$19M	+60.8%
Operating Income	-$11M	-$18M	+41.0%
Net Income	-$13M	-$18M	+27.6%

Revenue Segments

Product

$43M98%

Service

$658,0002%